Key result
34 mm Evolut-R achieves comparable technical success to smaller sizes with lower mean aortic gradients.
Why the study?
The study was conducted to evaluate and compare in-hospital, 1-month, and 1-year outcomes between patients treated with Evolut-R 34 mm versus smaller Evolut-R devices, and to identify predictors of at least mild paravalvular leaks.
Does TAVI with the Evolut-R 34 mm valve result in comparable clinical and procedural outcomes (technical success, PVL, PPM, MACCE, mortality) compared to smaller Evolut-R 23/26/29 mm valves in patients with severe aortic stenosis?
Cohort (n=269)
No
Does TAVI with the Evolut-R 34 mm valve result in comparable clinical and procedural outcomes (technical success, PVL, PPM, MACCE, mortality) compared to smaller Evolut-R 23/26/29 mm valves in patients with severe aortic stenosis?
The Evolut-R 34 mm valve demonstrates comparable safety, technical success, and 1-year clinical outcomes to smaller Evolut-R valves (23/26/29 mm) in patients with large aortic annuli, with pre-TAVI aortic peak velocity and calcium volume serving as independent predictors of at least mild paravalvular leak.
Answers are grounded in this paper and cite their sources.
May support 34 mm Evolut-R use in large annuli; leaves open randomized confirmation of durability.
OBJECTIVE: The main purpose of this study was to evaluate and compare the in-hospital, 1-month and 1-year post-procedure outcomes of patients treated with Evolut-R 34 mm and Evolut-R 23/26/29 mm devices. Additionally, the study aimed to identify factors that could predict the occurrence of ≥ mild paravalvular leaks (PVL). METHODS: Between April 2015 and May 2022, 269 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) with Evolut-R 34 mm (n = 66, 24.5%) and Evolut-R 23/26/29 mm (n = 203, 75.5%) devices in a single center were retrospectively analyzed. RESULTS: Patients in the Evolut-R 34 mm group had a lower female sex ratio (16.7% vs. 66.5%, P <.001, respectively), ejection fraction (50.7 ± 10.1% vs. 54.5 ± 9.3%, P =.016, respectively), and mean aortic gradient (7.4 ± 3.3 vs. 9.2 ± 5.0, P =.026, respectively) compared to the Evolut-R 23/26/29 mm group. The groups did not exhibit any statistically significant distinctions with regard to technical success, the need for a permanent pacemaker, occurrences of stroke, major vascular complications, PVL, major adverse cardiovascular and cerebrovascular events, or mortality. Peak velocity was confirmed as a significant predictor of ≥mild PVL in both patient groups in the receiver operating characteristic curve analysis. In logistic regression analysis; In patients with Evolut-R 34 mm valve, pre-TAVI aortic valve peak velocity (odds ratio (OR) = 23.202; P =.019) and calcium volume 800 Hounsfield Units (mm3) (OR = 1.017; P <.001) were independent predictors of ≥mild PVL. CONCLUSION: The Evolut-R 34 mm valve has shown comparable in-hospital results with smaller valve sizes. Pre-TAVI aortic valve peak velocity and calcium volume predicted ≥ mild PVL in Evolut-R 34 mm patients.
No takes yet. Share an insight, caveat, or question.
Raif Kılıç (2024) conducted a cohort in Symptomatic severe aortic stenosis undergoing TAVI (n=269). Evolut-R 34 mm transcatheter aortic valve vs. Evolut-R 23/26/29 mm transcatheter aortic valves was evaluated on Technical success (VARC-3 criteria). Evolut-R 34 mm valves achieved comparable technical success and complication rates to smaller Evolut-R sizes, with lower post-procedure mean aortic gradients.
Synapse has enriched 10 related papers. Consider them for comparative context: